Cancer and inflammation: implications for pharmacology and therapeutics.
Smoldering, nonresolving inflammation is a component of the tumor microenvironment. The linkage between inflammation and cancer, first perceived in the nineteenth century, is now part of an accepted paradigm of carcinogenesis.
Balkwill
F
F
Centre for Cancer and Inflammation, Institute of Cancer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK. f.balkwill@qmul.ac.uk
Mantovani
A
A
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D009369:Neoplasms / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control
D000893:Anti-Inflammatory Agents; D016207:Cytokines